Posted by Michael Wonder on 20 Feb 2020
FORMA Therapeutics announces FT-4202 granted fast track designation and rare paediatric disease designation for treatment of sickle cell disease
20 February 2020 - FORMA Therapeutics today announced the U.S. FDA has granted fast track designation and rare paediatric disease designation for its lead clinical asset, FT-4202, in development as a disease-modifying treatment for sickle cell disease.
FT-4202 is a selective pyruvate kinase-R activator that exhibits the potential to beneficially impact both anemia and vaso-occlusive crises for people living with sickle cell disease.
